Montanova trims Abeona Therapeutics stake to 0.9%
Montanova Capital, LLC and Aaron Cowen report their beneficial ownership of Abeona Therapeutics Inc. common stock on an amended Schedule 13G. They each report beneficial ownership of 500,000 shares of common stock, representing 0.9% of the outstanding class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Montanova Capital, LLC and Aaron Cowen report their beneficial ownership of Abeona Therapeutics Inc. common stock on an amended Schedule 13G. They each report beneficial ownership of 500,000 shares of common stock, representing 0.9% of the outstanding class.
Both reporting persons have shared voting and dispositive power over 500,000 shares and no sole voting or dispositive power. They indicate that they now hold 5 percent or less of the class. Each reporting person disclaims beneficial ownership of the securities beyond any pecuniary interest.
Key Figures
Key Terms
beneficial ownership financial
pecuniary interest financial
control person financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership in Abeona Therapeutics Inc. (ABEO) does Montanova Capital report?
How much of Abeona Therapeutics (ABEO) stock does Aaron Cowen beneficially own?
Does Montanova Capital still own more than 5% of Abeona Therapeutics (ABEO)?
What voting and dispositive powers do the ABEO reporting persons have?
Where are Montanova Capital and Abeona Therapeutics (ABEO) based according to this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.